Panion Financial Statements From 2010 to 2024

1760 Stock  TWD 89.50  0.20  0.22%   
Panion BF financial statements provide useful quarterly and yearly information to potential Panion BF Biotech investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Panion BF financial statements helps investors assess Panion BF's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Panion BF's valuation are summarized below:
Panion BF Biotech does not presently have any trending fundamental ratios for analysis.
Check Panion BF financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Panion BF's main balance sheet or income statement drivers, such as , as well as many indicators such as . Panion financial statements analysis is a perfect complement when working with Panion BF Valuation or Volatility modules.
  
This module can also supplement various Panion BF Technical models . Check out the analysis of Panion BF Correlation against competitors.

Panion BF Biotech Company Current Valuation Analysis

Panion BF's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Panion BF Current Valuation

    
  15.29 B  
Most of Panion BF's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Panion BF Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, Panion BF Biotech has a Current Valuation of 15.29 B. This is 6.42% higher than that of the Healthcare sector and 229.03% higher than that of the Biotechnology industry. The current valuation for all Taiwan stocks is 8.06% higher than that of the company.

Panion BF Biotech Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Panion BF's current stock value. Our valuation model uses many indicators to compare Panion BF value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Panion BF competition to find correlations between indicators driving Panion BF's intrinsic value. More Info.
Panion BF Biotech is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about  0.59  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Panion BF Biotech is roughly  1.68 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Panion BF's earnings, one of the primary drivers of an investment's value.

About Panion BF Financial Statements

Panion BF investors use historical fundamental indicators, such as Panion BF's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Panion BF. Please read more on our technical analysis and fundamental analysis pages.
Panion Bf Biotech Inc., a biotechnology pharmaceutical company, manufactures and sells various pharmaceutical products in Taiwan. Panion Bf Biotech Inc. was founded in 1976 and is headquartered in Taipei City, Taiwan. PANION BF operates under Biotechnology classification in Taiwan and is traded on Taiwan Stock Exchange.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Panion Stock Analysis

When running Panion BF's price analysis, check to measure Panion BF's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Panion BF is operating at the current time. Most of Panion BF's value examination focuses on studying past and present price action to predict the probability of Panion BF's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Panion BF's price. Additionally, you may evaluate how the addition of Panion BF to your portfolios can decrease your overall portfolio volatility.